Navigation Links
New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
Date:6/10/2008

BASEL, Switzerland, June 11 /PRNewswire-FirstCall/ --

- Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression

A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows that treating anaemia with NeoRecormon(R) (epoetin beta) has no negative impact on survival, tumour progression or deaths caused by blood clots, when used within its approved indications (1).

These encouraging results reported in the British Journal of Cancer, June 2008, showed no new safety concerns with NeoRecormon when used in accordance with its label and current EORTC guidelines.

Key findings of the meta-analysis

- No statistically significant difference in terms of overall survival

between patients receiving NeoRecormon or control.

- No statistically significant difference in disease progression between

NeoRecormon and the control groups, however there was a trend in favour

of a reduced risk of disease progression among NeoRecormon-treated

patients.

- There was an increased incidence of thromboembolic events (TEE) in the

NeoRecormon group (7.1% vs. 4.4%). This is consistent with the risk

observed in the erythropoiesis stimulating agent (ESA) class in

general, known by Health Authorities and described in all ESA labels.

There was no difference in the incidence of serious (4% vs. 3%) or

fatal TEEs (1% vs. 1%) for the NeoRecormon and control groups

respectively.

About the meta-analysis

- The meta-analysis was conducted to evaluate differences between

NeoRecormon and control (placebo or standard care) with regard to

overall survival, disease progression and TEEs.

- In contrast to other conventional meta-analyses, in this meta-analysis

individual patient level data and not study level data were used, which

allowed the conduct of more robust overall analysis and sub-analyses of

groups of special interest, such as those with haemoglobin (Hb) less#

than 11 g/dL.

- It included all 12 prospective, randomised, controlled studies in which

NeoRecormon was compared to placebo or standard treatment

(transfusions, if required) in patients with cancer undergoing

treatment with chemotherapy (7 studies), surgery (2 studies),

radiotherapy (2 studies) or radio-chemotherapy (1 study).

Since NeoRecormon was introduced nearly two decades ago, it has had an established safety and efficacy track record. Studies have confirmed that within its approved licence NeoRecormon has been shown to reduce the need for blood transfusions and to significantly improve quality of life for anaemic patients with cancer being treated with chemotherapy (2)(3)(4).

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Additional information about the Roche Group is available on the Internet at http://www.roche.com.

References

(1) Br J Cancer advance online publication 10 June 2008;

doi:10.1038/sj.bjc.6604408

(2) Br J Cancer. 2003 Apr 7;88(7):988-95

(3) Cancer Chemother Pharmacol. 2007 Jan;59(1):35-42

(4) J Clin Oncol. 2002 May 15;20(10):2486-94


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
2. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
3. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
4. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
5. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
8. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
9. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
10. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
11. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 , The data will be ... # 8006)   The conclusions of the study ... treated patients with 90% of the m presenting ... . Seventy two percent of the patients had clinical benefit. ... results from a Phase I study of plitidepsin in combination with bortezomib and ...
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
(Date:5/23/2016)... ... 2016 , ... During Logan University’s (Logan) Spring ... awarded $6,000 in chiropractic scholarships. The winners of the three $2,000 scholarships ... fifth trimester of classes at Logan. , “Standard Process has been extremely generous ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hospice of Westchester (HOW), ... for over 24 years, recently hosted its sixth annual Celebration of Life Memorial ... remembrance ceremonies, each concluding with the release of Monarch butterflies that honored the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... ... May 23, 2016 , ... While new ... epidemic (1), physicians are not legally required to follow them. In the absence ... 3, 4). Novus Medical Detox Center , a leading Florida-based drug treatment ...
Breaking Medicine News(10 mins):